Hodgkin's lymphoma is frequently associated with mast cell infiltration that correlates directly with disease severity, but the mechanisms underlying this relationship remain unclear. Here, we report that mast cells promote the growth of Hodgkin's tumor by modifying the tumor microenvironment. A transplantation assay shows that primary murine mast cells accelerate tumor growth by established Hodgkin's cell lines, and promote marked neovascularization and fibrosis. Both mast cells and Hodgkin's cells were sensitive to bortezomib, but mast cells were more resistant to bortezomib. However, bortezomib inhibited degranulation, PGE 2 -induced rapid release of CCL2, and continuous release of vascular endothelial growth factor-A from mast cells even at the concentration that did not induce cell death. Bortezomib-treated mast cells lost the ability to induce neovasculization and fibrosis, and did not promote the growth of Hodgkin tumor in vivo. These results provide further evidence supporting causal relationships between inflammation and tumor growth, and demonstrate that bortezomib can target the tumor microenvironment.
INTRODUCTION
Considerable evidence supports an initiating role of chronic inflammation in a proportion of malignancies. 1, 2 In man, inflammatory bowel diseases predispose to colorectal cancer, 3 chronic Helicobacter pylori infection is the leading cause of gastric cancer, 4 and hepatitis virus B or C infection predisposes to liver carcinoma. 5 Once established, many malignancies maintain an inflammatory component, perhaps due to persistence of the inflammation-initiating factors or to recruitment of inflammatory cells from the blood stream, resulting in various inflammatory cytokines being present at the tumor site. 2 Mast cells are commonly recognized at the margins of diverse tumors in man and rodents. [6] [7] [8] Mast cells can release numerous factors stored or newly synthesized after activation, resulting in modifying the tumor microenvironment.
Hodgkin's lymphoma (HL) is characterized by a few tumor cells, the Hodgkin and Reed-Sternberg cells, surrounded by many benign inflammatory cells including mast cells. 9 It has been reported that mast cell infiltration correlates with poor prognosis in HL. 10, 11 Compelling studies have revealed that CD30 ligand secreted from mast cells (MCs) could directly proliferate certain portions of HL cells. 12 However, the roles of MCs in HL have not been fully evaluated so far.
Bortezomib, a proteasome inhibitor, has emerged as an effective anticancer therapy toward a broad range of malignant hematological disorders and may have far-reaching potential in autoimmune disease including graft-versus-host disease because bortezomib can possess immuno-modulatory effects. 13, 14 However, the effects of bortezomib on mast cells are completely unknown so far.
In this study, we report that mast cells could promote the growth of Hodgkin tumor indirectly by modulating the tumor microenvironment and that bortezomib can target the mast cell functions by inhibiting secretion of mast cells products.
MATERIALS AND METHODS
Animal studies HDLM2, 4.0 Â 10 3 cells/well; BMMCs, 4.0 Â 10 3 cells/well; SPMCs, 4.0 Â 10 3 cells/well in 0.2 ml culture medium, four independent wells/group). After 72 h of incubation, 10 ml of TetraColor One reagent was added to each well, and absorbance at 450 nm was measured 4 h later. Proliferation of HL cells was calculated as follows: (optical density value of the mixture of HL cells and MCs À optical density value of MCs alone)/optical density value of HL cells alone.
HL transplantation assays
Six-week-old female NOD/SCID mice (Charles River Japan, Yokohama, Japan), were inoculated subcutaneously into the flank region above the hind leg with L428 (1.0 Â 10 7 cells in RPMI), KMH2 (1.0 Â 10 7 cells in RPMI) either alone or mixed with BMMC (1.0 Â 10 7 cells in RPMI). Total injection volume was 200 ml. To study the effects of bortezomib on mast cell functions to facilitate tumor growth, BMMCs were incubated for 96 h at 37 1C in complete culture medium alone or with the addition of bortezomib (5.0 nM). DMSO (0.1%) was used as a relevant control for bortezomib. BMMCs (5.0 Â 10 6 in RPMI) were washed twice with phosphate-buffered saline, and then were inoculated subcutaneously into six-week-old female NOD/SCID mice (six mice per group) together with intact L428 cells (5.0 Â 10 6 in RPMI). All animals were examined twice weekly; tumor size was calculated in mm 3 using the formula (length Â width 2 /2) as previously described. 18 The % of tumor size was calculated as follows: (tumor size with bortezomib-treated BMMCs/tumor size with intact BMMCs) Â 100. After measurement, HL cell tumors were removed, fixed in 10% neutral-buffered formalin solution (Sigma-Aldrich, St Louis, MO, USA), and embedded in paraffin. Tissues were sectioned (5 mm thickness), and slides were stained with Masson's trichrome and hematoxylin and eosin (Biopathology Institute Co., Ltd, Oita, Japan).
Human angiogenesis antibody array
The expression profile of angiogenesis-related proteins was detected and analyzed using human angiogenesis array kit (ARY007; R&D Systems, Minneapolis, MN, USA). This array contains duplicate spots of 55 angiogenesis-related proteins. A weakly angiogenic HL-60 cell line 19 was adopted as a reference. Briefly, the membrane containing immobilized angiogenesis-related antibodies was incubated with cell lysates from 1.0 Â 10 7 of L428 cells, KMH2 cells or HL-60 cells. Bound protein was detected with detection antibody cocktail (Amersham Pharmacia Biotech) and a chemiluminescence detection system (ECL kit; Amersham Pharmacia Biotech, Piscataway, NJ, USA). The membrane was scanned and the mean relative protein production level (target protein/GAPDH) from the two individual measurements was calculated by densitometric scanning using NIH image software (http://rsb.info.nih.gov/nih-image/). The obtained values were adjusted by protein loading control level in each membrane and shown expressed as the mean spot pixel densities.
Mouse angiogenesis antibody array
The expression profile of angiogenesis-related proteins in BMMCs before and after the bortezomib treatment was analyzed using the mouse angiogenesis array kit (ARY015; R&D Systems). Briefly, BMMCs (1.0 Â 10 7 ) were treated with/without bortezomib (5.0 nM) for 72 h and then were solubilized in lysis buffer. Hybridization of angiogenesis-related proteins to the membrane and detection of bound protein were similarly performed as described above. The obtained values were adjusted by protein loading control level in each membrane and shown expressed as the mean spot pixel densities.
In vitro and in vivo measurement of mast cell and HL cell viability after exposure to bortezomib MC and HL cell viability after exposure to bortezomib was assessed by trypan blue exclusion. Briefly, cells were washed twice with PBS, suspended in culture medium (RPMI containing 10% fetal bovine serum), plated (3.0 Â 10 4 cells/well in 0.2 ml culture medium) in four independent determinations with various concentrations (0-50 nM) of bortezomib onto 96-well plates, and incubated for 96 h. Viable cells were determined as Trypan blue-negative cells. In vivo MC viability after exposed to bortezomib was analyzed by using matrigel (BD Biosciences, San Jose, CA, USA). 
In vitro functional studies of bortezomib-treated MCs
Mast cells can release numerous factors stored or newly synthesized after activation through three different pathways: piecemeal degranulation, 21 rapid secretion without degranulation 22, 23 and degranulation. 24 To evaluate the effect of bortezomib on piecemeal degranulation, we measured vascular endothelial growth factor (VEGF)-A secretion. MCs (1.0 Â 10 6 cells/ml) were incubated in culture medium (RPMI 1640 containing 10% FCS) with/without bortezomib (5.0 nM). MC culture supernatants (four wells/subgroup) were obtained after cell culture for a period of 48, 72 and 96 h, and were used for VEGF-A detection by a specific ELISA (R&D Systems, Minneapolis, MN, USA). To study the effect of bortezomib on rapid secretion without and with degranulation, we measured CCL2 (CC chemokine ligand 2) secretion and b-hexosaminidase release, respectively. MCs (1.0 Â 10 6 cells/ml) were pretreated with bortezomib at 5.0 nM in complete culture medium for 72 h before addition of PGE 2 (1000 nM) or calcium ionophore A23187 (5 mM). After 1-h incubation with calcium ionophore A23187 or 6-h incubation with PGE 2 , cell-free supernatants were tested for CCL2 and b-Hexosaminidase release. All experiments were performed in triplicate. The percent release of MC products was calculated as follows: (MC product release in bortezomib group/CCL2 release in control group) Â 100 (%).
Statistical analysis
Statistical significance of group differences was evaluated by Student's t-test using Excel software (Microsoft, Redmond, WA, USA).
RESULTS

Effects of mast cells on the proliferation of HL cells in vitro
In vitro coculture assays showed that BMMCs weakly proliferated only KMH2 cells, and that SPMCs did not proliferate any Hodgkin lymphoma cells (Figure 1a) . (Figure 1b) . The mean size of tumors derived from inoculation of either L428 plus BMMC, KMH2 plus BMMC or HDLM2 plus BMMC were significantly greater (Po0.01, all comparisons) than the size of tumors derived from the inoculation of L428 alone, KMH2 alone or HDLM2 alone, respectively. We had confirmed that BMMC alone did not form tumors. 20 Microscopically, tumors derived from inoculation of L428, KMH2 and HDLM2 HL cells together with mast cells possessed increased vasculature identified by their content of red blood cells and fibrosis, whereas tumors derived from inoculation of HL cells alone were generally hypovascularized with less fibrosis and were necrotic in most of areas (Figure 1c) . Interestingly, MCs, identified by cytochemical staining with toluidine blue (purple), localized in the proximity of vessels (Figure 1c, insets) .
L428 and KMH2 Hodgkin lymphoma cells minimally produce proangiogenic factors To determine proangiogenic factors released by HL cell lines, we performed an antibody array using cell lysates from L428 cells, KMH2 cells or HL-60 cells. A weakly angiogenic HL-60 cell line was adopted as a reference. As shown in Table 1 , L428 cells and KMH2 cells rarely produced proangiogenic factors except for VEGF-A and fibroblast growth factor-2. L428 cells and KMH2 cells weakly produce VEGF-A compared with HL-60. Both L428 cells and KMH2 produce fibroblast growth factor-2 in similar levels of VEGF.
Mast cells are sensitive to bortezomib, but are more resistant than HL cells We exposed MCs and HL cells continuously to increasing concentrations of bortezomib and quantified the viabilities by trypan blue exclusion 96 h later. Bortezomib induced a minimal cell death in MCs at concentrations as low as 5 nM with about 50% of cell death observed at a concentration of 10 nM (Figure 2a) . However, more than 90% of HL cells were dead at the 10 nM bortezomib (Figure 2b ). These results clearly suggest that MCs are more resistant to bortezomib than HL cells.
Bortezomib perturbs mast cell functions at the dose that minimally affects on mast cell viabilities We tested effects of bortezomib on mast cell functions to release numerous factors stored or newly synthesized after activation. After 72-h incubation with bortezomib (5 nM), calcium ionophore A23187-and PGE 2 -activated BMMC and SPMCs released significantly less b-hexosaminidase and CCL2, respectively, compared with BMMC and SPMCs not treated with bortezomib (Figures 3a  and b) . Using a specific ELISA to measure VEGF-A in culture supernatants, we found that bortezomib can decrease by approximately 50% the levels of VEGF-A released by BMMCs and SPMCs (Figure 3c ). We also tested effects of bortezomib on expression of other proangiogenic factors in BMMC by using an antibody array using cell lysates from BMMCs before and after bortezomib treatment (5 nM for 96 h). As summarized in Table 2 , bortezomib treatment profoundly decreased expression of angiopoietin-1, endoglin, heparin binding-epidermal growth factor(HB-EGF) and VEGF-B, but not PAI-1. These decreased levels of proangiogenic factors in MCs culture supernatants and/or cytoplasm could not be attributed to decreased MC numbers, as 96-h treatment with bortezomib at a 5 nM minimally affected on mast cell viabilities (Figure 2a ).
Bortezomib-treated MCs lost the abilities to promote the growth of HL cell tumors in vivo
We tested for the contribution of mast cell functions to the tumor growth of HL cells in vivo by using bortezomib. First, we analyzed in vivo MC viability after exposed to bortezomib by using matrigel. MCs (0.5 Â 10 6 ) were treated with/without Bortezomib (5.0 nM) for 72 h and then mixed with 0.5 ml of Matrigel. The mixtures were injected subcutaneously into the mid-abdominal region of female NOD/SCID 6-to 8-week-old mice (five mice per group). After 7 days, Matrigel plugs were removed. Toluidine blue staining showed that there was no significant difference in the number of viable MCs treated with/without bortezomib ( Figure 4a) . Next, NOD/SCID mice (six mice per group) were inoculated subcutaneously with L428 cells or KMH2 cells (5.0 Â 10 6 ) in conjunction with BMMCs (5.0 Â 10 6 ) treated with/without bortezomib (5.0 nM). The mean size of tumors derived from inoculation of L428 or KMH2 plus intact BMMCs were significantly greater than the size and weight of tumors derived from inoculation of L428 or KMH2 plus bortezomib-treated BMMCs (Figure 4b) . Microscopically, tumors derived from inoculation of L428 or KMH2 HL cells together with intact MCs were highly vascularized and fibrotic, whereas tumors derived from inoculation of L428 or KMH2 cells plus bortezomib-treated MCs were generally not (Figure 4c ). These results confirm that bortezomib is effective at inhibiting the MC-induced growth of Hodgkin's cell tumors in vivo by blocking the release of secretary granules from MCs.
DISCUSSION
Evidence that pathological changes associated with inflammation in the tumor microenvironment promote tumorigenesis has been obtained in experimental model systems and clinical settings. 2, 25, 26 It has been reported that mast cell infiltration correlates with poor prognosis in HL. 10, 11 However, mouse MCs do not directly proliferate all of HL cells (Figure 1a) . A previous study has shown that human MCs, when the same number of MCs and HL cells were cocultured, proliferated weakly but significantly HL cells. 27 This discrepancy of effectiveness may result from different origins of MCs. Interestingly, when the same number of murine MCs and HL cells were inoculated subcutaneously in NOD/ SCID, L428, KMH2 cells and HDLM2 cells gave rise to significantly larger tumors compared with HL cells alone (Figure 1b) . Microscopic analysis showed that tumors derived from inoculation of HL cells together with mast cells possessed increased vasculature, whereas tumors derived from inoculation of HL cell alone generally did not (Figure 1c) . Thus, we provide direct evidence that mast cells have an ability to promote the growth of HL cell tumors indirectly through modulating the microenvironment. The oxygen and nutrients supplied by the vasculature are crucial for 28 Protein array analysis showed that L428 and KMH2 HL cells minimally produce proangiogenic factors (Table 1) , while mast cells are rich in proangiogenic factors. 20 Thus, MCs must be indispensable for HL cells to propagate themselves. Mast cells also induced fibrosis in HL cell tumors (Figure 1c) as reported in various tissues in human diseases. 29, 30 Quantitative studies of mast cells in human specimens of HL showed that nodular sclersosis contained many more mast cells than the other subtypes. 31, 32 Physical forces such as compression and tension forces induced by fibrosis can help cancer progression and tumor cell invasion through promoting angiogenesis, accumulating the fluid from leaky blood and lymphatic vessels and increasing the local concentration of growth factors and cytokines to facilitate autocrine and paracrine signaling. 33 Taken together, fibrosis induced by mast cells could not only determine the subtype of HL but also contribute to HL progression.
Bortezomib, a proteasome inhibitor, exerts anticancer activity mainly by inhibiting NF-kB, which has a pivotal role in synthesis of antiapoptotic factors, such as c-Flip, inhibitor of apoptosis (IAP) 1/2, and Bcl-2, and of angiogenic factors. 34 In addition to their anticancer properties, bortezomib modulates inflammatory and immune responses by affecting function and survival of immune cells such as lymphocytes and dendritic cells. 35 However, unique contributions of bortezomib to mast cell functions have not been previously demonstrated. Here we show that bortezomib not only inhibits the three distinct ways of release of secretary granules from MCs but also decrease expression of proangiogenic factors probably due to blocking the NF-B pathway as compelling studies revealed that NF-kB activation can be involved in production and/ or secretion of cytokines, chemokines and chemical mediators from MCs. [36] [37] [38] 
